Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
Authors
Keywords
-
Journal
Cells
Volume 11, Issue 13, Pages 2058
Publisher
MDPI AG
Online
2022-06-29
DOI
10.3390/cells11132058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
- (2021) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
- (2020) Peter Alping et al. ANNALS OF NEUROLOGY
- Ponesimod for the treatment of relapsing multiple sclerosis
- (2020) Elisa Baldin et al. EXPERT OPINION ON PHARMACOTHERAPY
- Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases
- (2019) Bisera Stepanovska et al. PHARMACOLOGICAL RESEARCH
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
- (2018) Andrea Huwiler et al. PHARMACOLOGY & THERAPEUTICS
- Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
- (2018) Kristen R. Taylor Meadows et al. PLoS One
- Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
- (2017) Jonathan Q. Tran et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Implication of sphingosine-1-phosphate signaling in diseases: molecular mechanism and therapeutic strategies
- (2017) Mohd Arish et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia
- (2017) Bhakta Prasad Gaire et al. MOLECULAR NEUROBIOLOGY
- Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells
- (2017) Nigel Pyne et al. MOLECULES
- Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
- (2017) Burhan Z. Chaudhry et al. Neurotherapeutics
- Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition
- (2017) Ranjeet Prasad Dash et al. XENOBIOTICA
- Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism
- (2017) Marc Bigaud et al. PLoS One
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
- (2016) F L Scott et al. BRITISH JOURNAL OF PHARMACOLOGY
- Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis
- (2016) Nasr Y. A. Hemdan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
- (2016) Antonietta Gentile et al. Journal of Neuroinflammation
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis
- (2016) Edward R. Hammond JAMA Neurology
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks
- (2016) Kira V. Blankenbach et al. Frontiers in Pharmacology
- Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
- (2016) Daniele D’Ambrosio et al. Therapeutic Advances in Chronic Disease
- Phenotypic Regulation of the Sphingosine 1-Phosphate Receptor Miles Apart by G Protein-Coupled Receptor Kinase 2
- (2015) Martina Burczyk et al. BIOCHEMISTRY
- Subcellular distribution of FTY720 and FTY720-phosphate in immune cells – another aspect of Fingolimod action relevant for therapeutic application
- (2015) Matthias Schröder et al. BIOLOGICAL CHEMISTRY
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
- The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
- (2015) Sathya Narayanan Patmanathan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
- (2015) Jeffrey A Cohen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation
- (2015) Victoria A. Blaho et al. NATURE
- 36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice
- (2015) T Ziemssen et al. VALUE IN HEALTH
- Lysophospholipid receptor nomenclature review: IUPHAR Review 8
- (2014) Yasuyuki Kihara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Differential effects of ponesimod, a selective S1P1receptor modulator, on blood-circulating human T cell subpopulations
- (2014) Daniele D'Ambrosio et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Knock Out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model
- (2014) Ken Murakami et al. PLoS One
- Impact of an immune modulator fingolimod on acute ischemic stroke
- (2014) Ying Fu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fingolimod for the Treatment of Intracerebral Hemorrhage
- (2014) Ying Fu et al. JAMA Neurology
- Second generation S1P pathway modulators: Research strategies and clinical developments
- (2013) Marc Bigaud et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study
- (2013) Patrick Brossard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
- (2013) Ralf Gold et al. JOURNAL OF NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis
- (2013) Anthony O. Awojoodu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Brain-Immune Interactions and Ischemic Stroke
- (2012) Costantino Iadecola ARCHIVES OF NEUROLOGY
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3receptor ligands using the DiscoveRx PathHunter™ and Ca2+release functional assays
- (2012) DM Riddy et al. BRITISH JOURNAL OF PHARMACOLOGY
- A Potent and Selective S1P1 Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis
- (2012) Jean Quancard et al. CHEMISTRY & BIOLOGY
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
- (2011) L. Piali et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation
- (2011) T. Hla et al. NEUROLOGY
- Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
- (2011) C. Christoffersen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sphingosine-1-phosphate signaling and its role in disease
- (2011) Michael Maceyka et al. TRENDS IN CELL BIOLOGY
- Sphingosine-1-Phosphate Receptor-2 Function in Myeloid Cells Regulates Vascular Inflammation and Atherosclerosis
- (2010) Athanasia Skoura et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- S1P metabolism in cancer and other pathological conditions
- (2010) Weng In Leong et al. BIOCHIMIE
- Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation
- (2010) Ashley J. Snider et al. BIOCHIMIE
- Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4
- (2010) Sven Golfier et al. FASEB JOURNAL
- Sphingosine 1-Phosphate (S1P) Regulates Vascular Contraction via S1P3 Receptor: Investigation Based on a New S1P3 Receptor Antagonist
- (2010) A. Murakami et al. MOLECULAR PHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs
- (2009) Frank W. Foss et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
- (2009) Florian Mullershausen et al. Nature Chemical Biology
- New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets
- (2008) Andrea Huwiler et al. BIOCHEMICAL PHARMACOLOGY
- Dendritic cell PAR1–S1P3 signalling couples coagulation and inflammation
- (2008) Frank Niessen et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started